What's Behind The Jump In ImmunityBio Stock?

Bladder Cancer Treatment Receives ApprovalThe authorization by the European Commission allows ImmunityBio to establish a substantial commercial footprint across four regulatory jurisdictions in less than two years from its initial FDA approval. This rapid expansion is pivotal as it includes key markets like the Kingdom of Saudi Arabia, where ANKTIVA has received authorization for two indications, highlighting its growing acceptance and potential impact on ImmunityBio’s market reach.As part of the conditiona ...